UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 30, 2018

AETHLON MEDICAL, INC.

(Exact name of registrant as specified in its charter)

Nevada	001-37487
(State or other jurisdiction of incorporation)	(Commission File Number)

9635 Granite Ridge Drive, Suite 100 San Diego, California	92123
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (858) 459-7800

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by checkmark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934

Emerging growth company. ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

FORWARD-LOOKING STATEMENTS

This Form 8-K and other reports filed by Registrant from time to time with the Securities and Exchange Commission (collectively, the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well as estimates and assumptions made by Registrant's management. When used in the Filings the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to Registrant or Registrant's management identify forward-looking statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Although Registrant believes that the expectations reflected in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.

ITEM 8.01 Other Events

On October 30, 2018, Jim Joyce, the Company's Chief Executive Officer, made the attached presentation at the NYC Oncology Conference in New York City, NY.

ITEM 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Presentation at the October 30, 2018 NYC Oncology Conference

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AETHLON MEDICAL, INC.

By: /s/ James B. Frakes
James B. Frakes
Chief Financial Officer

Dated: Ocober 30, 2018

Exhibit 99.1



Image of Ebola viruses exiting host cells - Courtesy of NIAID

NYC Oncology Conference

NASDAQ: AEMD - MARKET CAP: ~$20M

JIM JOYCE - FOUNDER & CEO

OCTOBER 30, 2018

aethlon MEDICAL, INC.

FORWARD LOOKING STATEMENTS

The following presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com

TO ADDRESS UNMET NEEDS IN GLOBAL HEALTH

aethlon MEDICAL, INC.

TO SAVE LIVES

aethlon MEDICAL, INC.

A FIRST-IN-CLASS THERAPEUTIC TECHNOLOGY

THE HEMOPURIFIER®

DESIGNED FOR THE SINGLE-USE DEPLETION OF CIRCULATING VIRUSES AND CANCER-PROMOTING EXOSOMES

aethlon MEDICAL, INC.

DEPLOYED FOR USE ON THE GLOBAL INFRASTRUCTURE OF DIALYSIS & CRRT INSTRUMENTS



THE HEMOPURIFIER®

DESIGNED FOR THE SINGLE-USE DEPLETION OF CIRCULATING VIRUSES AND CANCER-PROMOTING EXOSOMES

aethlon MEDICAL, INC.

The Aethlon Hemopurifier®

Mechanism of Action

- Full circulation depletion of viruses and cancer promoting exosomes
- Targets are glycan shielded to evade the host immune response
- Combination Mechanism of Action
  - Plasma separation / lectin affinity capture

aethlon MEDICAL, INC.

The Aethlon Hemopurifier®

Viral Clinical accomplishments

- *In vitro* Capture validations of 15 high-threat viral pathogens
- Completed Four investigational human studies outside U.S.
- Concluded U.S. human feasibility study (March 2017)
- Received "expedited Access Pathway" (EAP) Designation from FDA (September 2017)

aethlon MEDICAL, INC.

THE AETHLON HEMOPURIFIER®

Designated a "Breakthrough Device" by FDA

THE HEMOPURIFIER® IS AN FDA DESIGNATED "BREAKTHROUGH DEVICE" FOR THE TREATMENT OF LIFE-THREATENING GLYCOSYLATED VIRUSES THAT ARE NOT ADDRESSED WITH APPROVED THERAPIES.



Ebola Image Courtesy of NIAID

Frankfurt University Hospital

EMERGENCY-USE APPROVAL FROM GERMANY'S FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES (BFARM) TO ADMINISTER HEMOPURIFIER® THERAPY TO AN EBOLA-INFECTED PHYSICIAN AT FRANKFURT UNIVERSITY HOSPITAL.

THE TREATMENT OF EBOLA VIRUS



A SINGLE 6.5-HOUR ADMINISTRATION OF HEMOPURIFIER® THERAPY WAS DELIVERED TO THE PATIENT, WHO WAS COMATOSE WITH MULTIPLE ORGAN FAILURE.

aethlon MEDICAL, INC.

Ebola Treatment Results

Presented at the American Society of Nephrology Annual Meeting by Helmut Geiger, M.D., Chief of Nephrology at Frankfurt University Hospital

- Hemopurifier® therapy was well tolerated with no adverse events
- Pre-treatment viral load prior was measured to be 400,000 copies/ml
- Post-treatment viral load was measured at 1,000 copies/ml
- Patient made a full recovery

aethlon MEDICAL, INC.

THE TREATMENT OF EBOLA VIRUS

DR. STEFAN BÜTTNER HOLDING THE HEMOPURIFIER® AFTER TREATMENT OF EBOLA VIRUS

aethlon MEDICAL, INC.

VIRUS CAPTURE ASSAY RESULT

253 MILLION COPIES OF EBOLA VIRUS CAPTURED WITHIN THE HEMOPURIFIER® DURING THE 6.5 HOUR TREATMENT

Analysis: BSL4 Lab
Philipps University Marburg
(O. Dolnik/M. Eickmann/S. Becker)

aethlon MEDICAL, INC.

THE HEMOPURIFIER® TO TREAT CANCER?

ADDRESSING A SIGNIFICANT UNMET NEED IN CANCER CARE

TUMOR DERIVED EXOSOMES (TEX)

A SIGNIFICANT UNMET NEED IN CANCER CARE



Image of exosomes being released by a tumor cell

TUMOR DERIVED EXOSOMES (TEX)

A SIGNIFICANT UNMET NEED IN CANCER CARE

- TEX SEED THE SPREAD OF METASTASIS (ASSOCIATED WITH 90% OF CANCER DEATHS)
- TEX PROMOTE IMMUNE SUPPRESSION & DIRECTLY INHIBIT T-CELL RESPONSE
- TEX PREVALENCE CORRELATES WITH CANCER PROGRESSION
- TEX PROMOTE CANCER THERAPY RESISTANCE
  - A BASIS FOR PARTNERING OPPORTUNITIES
  - PATHWAY INTO WELL-DEFINED MARKETS



Data Source: Numerous Peer-Reviewed Publications

aethlon MEDICAL, INC.

TUMOR DERIVED EXOSOMES (TEX)

PROMOTING RESISTANCE TO CANCER THERAPIES

- TEX DECOY CHEMOTHERAPEUTIC AGENTS
- TEX INHIBIT HIGH-VALUE CAR-T THERAPIES
  - JUNO ACQUIRED FOR $9 BILLION BY CELGENE
  - KITE ACQUIRED FOR $11.9 BILLION BY GILEAD
- TEX PROMOTE ANTI-CANCER DRUG RESISTANCE
  - INCLUDING PD-1 CHECKPOINT INHIBITORS
  - KNOWN TO INHIBIT 7 OF TOP 10 CANCER DRUGS



Data Source: Numerous Peer-Reviewed Publications

aethlon MEDICAL, INC.

7 OF TOP 10 CANCER DRUGS

TUMOR-DERIVED EXOSOMES KNOWN TO INHIBIT TREATMENT EFFICACY



Market Data Source: ProClinical
Drug Resistance Data Source: PubMed Peer-Reviewed Publications

aethlon MEDICAL, INC.

TUMOR DERIVED EXOSOMES (TEX)

LINKS TO DRUG RESISTANCE PUBLICATION REFERENCES

- RITUXIN - WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/PMC3174603
- AVASTIN - WWW.NATURE.COM/ARTICLES/NCOMMS14450
- HERCEPTIN - WWW.NCBI.NLM.NIH.GOV/PMC/ARTICLES/PMC5706614/
- IMBRUVICA - WWW.HAEMATOLOGICA.ORG/CONTENT/102/9/1594
- GLEEVEC - WWW.NCBI.NLM.NIH.GOV/PUBMED/29223442
- VELCADE - WWW.NCBI.NLM.NIH.GOV/PUBMED/24928860
- ERBITUX - WWW.NCBI.NLM.NIH.GOV/PUBMED/29160412



Data Source: Numerous Peer-Reviewed Publications

aethlon MEDICAL, INC.

INTEREST IN THE HEMOPURIFIER TO TREAT CANCER

FOLLOWING PUBLICATION HAS BEEN CITED 183 TIMES

J Transl Med. 2012 Jun 27;10:134. doi: 10.1186/1479-5876-10-134.

EXOSOME REMOVAL AS A THERAPEUTIC ADJUVANT IN CANCER

Marleau AM1, Chen CS, Joyce JA, Tullis RH.

Author information

1: Aethlon Medical Inc, 8910 University Center Lane, Suite 660, San Diego, CA92122, USA. annette@aethlonmedical.com

Abstract

Exosome secretion is a notable feature of malignancy owing to the roles of these nanoparticles in cancer growth, immune suppression, tumor angiogenesis and therapeutic resistance. Exosomes are 30-100 nm membrane vesicles released by many cells types during normal physiological processes. Tumors aberrantly secrete large quantities of exosomes that transport oncoproteins and immune suppressive molecules to support tumor growth and metastasis. The role of exosomes in intercellular signaling is exemplified by human epidermal growth factor receptor type 2 (HER2) over-expressing breast cancer, where exosomes with the HER2 oncoprotein stimulate tumor growth and interfere with the activity of the therapeutic antibody Herceptin®. Since numerous observations from experimental model systems point toward an important clinical impact of exosomes in cancer, several pharmacological strategies have been proposed for targeting their malignant activities. We also propose a novel device strategy involving extracorporeal hemofiltration of exosomes from the entire circulatory system using an affinity plasmapheresis platform known as the Aethlon ADAPT™ (adaptive dialysis-like affinity platform technology) system, which would overcome the risks of toxicity and drug interactions posed by pharmacological approaches. This technology allows affinity agents, including exosome-binding lectins and antibodies, to be immobilized in the outer-capillary space of plasma filtration membranes that integrate into existing kidney dialysis systems. Device therapies that evolve from this platform allow rapid extracorporeal capture and selective retention of target particles < 200 nm from the entire circulatory system. This strategy is supported by clinical experience in hepatitis C virus-infected patients using an ADAPT™ device, the Hemopurifier®, to reduce the systemic load of virions having similar sizes and glycosylated surfaces as cancer exosomes. This review discusses the possible therapeutic approaches for targeting immune suppressive exosomes in cancer patients, and the anticipated significance of these strategies for reversing immune dysfunction and improving responses to standard of care treatments.

2018 CANCER INITIATIVES

NIH/NCI Contract

2018 Initiative #1

- "Device Strategy for selective isolation of oncosomes and non-malignant exosomes"
- Completed June 2018
- Demonstrated isolation and capture of metastatic melanoma exosomes
    - Preparing Phase II contract submission (valued at $2 million)

NIH/NCI Contract

2018 Initiative #2

- "The Hemopurifier device for targeted removal of breast cancer exosomes from the blood circulation"
- Contract award on September 18, 2018
- Program initiated

- "Plasma exosome concentration in cancer patients undergoing treatment"
- Multi-indication enrollment of cancer patients
- Demonstrated (May-August 2018) *in vitro* capture of exosomes underlying:
  - Breast cancer
  - Esophageal cancer
  - Ovarian cancer

NIH/NCI SUBMISSION

2018 INITIATIVE #4

- HUMAN CLINICAL STUDY PROPOSAL ENTITLED: "DEPLETING EXOSOMES TO IMPROVE RESPONSES TO IMMUNE THERAPY IN HEAD AND NECK CANCER SQUAMOUS CELL CANCER"
- ADJUNCT STUDY WITH OPDIVO
- CURRENTLY PENDING REVIEW PANEL DECISION

FDA Breakthrough Device Submission

2018 Initiative #5

- "Use of the Aethlon Hemopurifier as an adjunct therapy in patients with diagnosed metastatic cancer"
  - Breakthrough submission on September 25, 2018
  - Pending decision from FDA

DOD/U.S. Army Breakthrough Award

2018 Initiative #6

- "Isolation of triple negative breast cancer Exosomes using the Hemopurifier"
- Department of defense (DOD) congressionally directed medical research program (CDMRP), breast cancer breakthrough research award
  - Award notification on October 23, 2018
    - Pending completion of contracting process

A FIRST-IN-CLASS THERAPEUTIC TECHNOLOGY

THE HEMOPURIFIER®

DESIGNED FOR THE SINGLE-USE DEPLETION OF CIRCULATING VIRUSES AND CANCER PROMOTING EXOSOMES

aethlon MEDICAL, INC.

TO ADDRESS UNMET NEEDS IN GLOBAL HEALTH

aethlon MEDICAL, INC.

TO SAVE LIVES

9635 Granite Ridge Drive, Suite 100
San Diego, California 92123
858.459.7800
Nasdaq: AEMD
www.AethlonMedical.com

This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully developed and introduced; market acceptance of the Aethlon Hemopurifier® and other product offerings; regulatory delays, manufacturing delays, and other risks detailed in our SEC filings, which are accessible at www.sec.gov or on our website: www.AethlonMedical.com